New strategies for control of respiratory syncytial virus infection

@article{Nokes2008NewSF,
  title={New strategies for control of respiratory syncytial virus infection},
  author={James Nokes and Patricia A. Cane},
  journal={Current Opinion in Infectious Diseases},
  year={2008},
  volume={21},
  pages={639–643}
}
  • J. Nokes, P. Cane
  • Published 2008
  • Medicine
  • Current Opinion in Infectious Diseases
Purpose of review To report on recent progress on the development and implementation of a vaccine against respiratory syncytial virus (RSV), on investigations of the mechanism of action of prophylactic antibodies and the potential for increased efficacy of those antibodies, and on candidate antiviral drugs against RSV. Recent findings Follow-up data from RSV live attenuated vaccine trials in naïve infants and young children strengthen the view that live attenuated vaccines will not predispose… Expand
Respiratory syncytial virus: an overview of infection biology and vaccination strategies
TLDR
This review will help in understating the RSV pathobiology and encompass the advancement on various vaccine candidates that would lead to reduce the incidence, mortality and morbidity, and lighten up the different avenues which might be useful for the development of novel vaccination approaches. Expand
Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein
TLDR
The RSV envelope glycoprotein F plays an important role in RSV fusion with, and entry into, the host cell and, consequently, serves as an attractive target for developing RSV entry inhibitors. Expand
Pneumonia Virus of Mice (PVM): Exploring Novel Therapeutic Options In a Severe Respiratory Disease Model
TLDR
Several immunomodulatory strategies that clearly reduce morbidity and mortality when administered to PVM infected, symptomatic mice hold promise as realistic therapeutic strategies for severe RSV infection in human subjects. Expand
Transmission of Respiratory Syncytial Virus in Households: Who Acquires Infection From Whom?
TLDR
These findings support vaccination strategies that target school age children and pregnant women by augmenting neutralizing antibodies against RSV and indirectly by reducing transmission from siblings to RSV-naive infants. Expand
Prospects for defined epitope vaccines for respiratory syncytial virus.
TLDR
C cumulative data on murine and human CD4, CD8 and neutralization epitopes identified in RSV proteins along with information regarding their associated immune responses and host-dependent variability are presented. Expand
Antigen-based assays for the identification of influenza virus and respiratory syncytial virus: why and how to use them in pediatric practice.
TLDR
Rapid tests for the detection and identification of IV and RSV in the respiratory secretions of infants and children are useful in the diagnosis of common, and possibly severe diseases, such as influenza and bronchiolitis. Expand
The Source of Respiratory Syncytial Virus Infection In Infants: A Household Cohort Study In Rural Kenya
TLDR
It is demonstrated that school-going siblings frequently introduce RSV into households, leading to infection in infants, and the potential of indirect protection using different strategies, such as targeting older children or mothers, is assessed. Expand
Respiratory Syncytial Virus
TLDR
Human respiratory syncytial virus is a ubiquitous ribonucleic acid (RNA) virus that represents the leading cause of acute lower respiratory infections in infants and young children worldwide and there is still no licensed prophylactic HRSV vaccine available. Expand
EFFICACY AND SAFETY OF VIRUS LIKE PARTICLE VACCINES AGAINST RESPIRATORY SYNCYTIAL VIRUS IN MOUSE AND COTTON RAT MODELS
TLDR
Evidence is provided that FFG VLP, FG VLP and F VLP are worthwhile for further development into a safe RSV vaccine candidate and inclusion of F V LP in the G VLP vaccination could improve vaccine safety in cotton rats. Expand
Respiratory syncytial virus infection in children.
TLDR
Children younger than two years at high risk of severe illness, including those born before 35 weeks of gestation and those with chronic lung or cardiac problems, may be candidates for palivizumab prophylaxis for RSV infection during the peak infection season. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
RSV604, a Novel Inhibitor of Respiratory Syncytial Virus Replication
TLDR
The discovery and initial development of RSV604, a novel benzodiazepine with submicromolar anti-RSV activity, which proved to be equipotent against all clinical isolates tested of both the A and B subtypes of the virus. Expand
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
TLDR
In the present study, the rate of RSV-associated upper respiratory tract illness in 388 children was lower in RSV vaccinated children than in controls, and infection with a series of live attenuated RSV vaccines did not result in enhanced disease upon infection with wild type RSV. Expand
Immunoglobulin for preventing respiratory syncytial virus infection.
  • E. Wang, N. Tang
  • Medicine
  • The Cochrane database of systematic reviews
  • 2000
TLDR
This meta-analysis was performed to assess the effects of polyclonal respiratory syncytial virus hyperimmune globulin or monoclonal antibody in preventing RSV hospitalization, receipt of intensive care, mechanical ventilation, and mortality in those with underlying prematurity, bronchopulmonary dysplasia, or congenital heart disease. Expand
Respiratory Syncytial Virus Infects and Abortively Replicates in the Lungs in Spite of Preexisting Immunity
TLDR
It is found that passive administration of antibodies to RSV prevents productive infection normally accompanied by viral release in the lung, but it does not prevent abortive replication of the virus. Expand
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
  • P. Wright, R. Karron, +15 authors B R Murphy
  • Biology, Medicine
  • The Journal of infectious diseases
  • 2000
TLDR
The cpts-248/404 vaccine candidate was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants, and was unacceptable in the youngest infants because of upper respiratory tract congestion associated with peak virus recovery. Expand
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
TLDR
The development and characterization of motavizumab is reported, an ultra-potent, affinity-matured, humanized mAb derived from palivizumac, an affinity-enhanced mAb being investigated in pivotal clinical trials and offers precious insights into the improvement of other therapeutic mAbs. Expand
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
BACKGROUND Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations. METHODS Two liveExpand
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.
TLDR
Deletion of the NS2 gene attenuates RSV in subjects of all ages studied validates the strategy of developing live respiratory tract virus vaccines in which the virus's ability to inhibit the human innate immune system is blocked. Expand
Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
  • D. Nokes, E. Okiro, +6 authors G. Medley
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2008
TLDR
RSV accounts for a substantial proportion of the total respiratory disease in this rural population in Kenya and the majority of this morbidity occurs during late infancy and early childhood--ages at which the risk of disease following infection remains significant. Expand
Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection.
TLDR
Post-infection intranasal or aerosolized treatment with pyrimidine synthesis inhibitors may provide symptomatic relief from the pathophysiologic sequelae of impaired AFC in children with RSV bronchiolitis. Expand
...
1
2
3
...